海爾生物(688139.SH)業績快報:2020年淨利升109.24%至3.81億元
格隆匯2月22日丨海爾生物(688139.SH)披露2020年度業績快報,報吿期內,公司實現營業總收入14.02億元,同比增長38.47%;營業利潤4.28億元,同比增長98.17%;利潤總額4.24億元,同比增長100.98%;歸屬於母公司所有者的淨利潤3.81億元,同比增長109.24%;歸屬於母公司所有者的扣除非經常性損益的淨利潤3.14億元,同比增長87.88%。
報吿期的經營情況、財務狀況及影響經營業績的主要因素系:
1、報吿期內,公司聚焦物聯網轉型戰略,持續進行研發投入推進技術及產品方案的迭代,加速推進渠道及網絡的拓展和佈局,在實現物聯網產品及方案收入快速增長的同時,原有優勢產品亦保持持續快速增長。
2、公司處置子公司青島海美康濟生物科技有限公司取得投資收益,同時積極使用暫時閒置資金進行現金管理取得理財收益,非經常性損益較上年同期增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.